US Govt. Injects $100's of Millions Into Lithium
The government's cash infusion could send lithium exploration companies soaring. They're desperate for new lithium mines to end China's Lithium Monopoly. See how you could take advantage of this enormous cash infusion.
Click Here To Read The Full Story
Marcio Souza, insider at Praxis Precision Medicines

Marcio Souza Insider Information

Marcio Souza has served as a director and our President and Chief Executive Officer since April 2020. Prior to joining us, Mr. Souza was at PTC Therapeutics, Inc., or PTC, where he served as its Chief Operating Officer from May 2017 to April 2020 and its Senior Vice President and Head of Product Strategy from July 2016 to May 2017. Prior to joining PTC, Mr. Souza served in positions of increasing responsibility at NPS Pharmaceuticals, Inc., Shire Human Genetic Therapies Inc. and Sanofi Genzyme Corporation. From May 2019 to May 2020, Mr. Souza also served on the board of directors of Clearpoint Neuro, Inc. (previously MRI Interventions, Inc.). Mr. Souza received a degree in pharmacy and biochemistry with a specialization in toxicology and clinical analysis from the University of São Paulo and an M.B.A. from Fundação Dom Cabral.

What is Marcio Souza's net worth?

The estimated net worth of Marcio Souza is at least $452,149.76 as of June 8th, 2022. Mr. Souza owns 189,184 shares of Praxis Precision Medicines stock worth more than $452,150 as of June 29th. This net worth approximation does not reflect any other assets that Mr. Souza may own. Additionally, Mr. Souza receives a salary of $1,240,000.00 as CEO at Praxis Precision Medicines. Learn More about Marcio Souza's net worth.

How old is Marcio Souza?

Mr. Souza is currently 42 years old. There are 4 older executives and no younger executives at Praxis Precision Medicines. Learn More on Marcio Souza's age.

What is Marcio Souza's salary?

As the CEO of Praxis Precision Medicines, Inc., Mr. Souza earned a total compensation package of $11,741,959.00 in 2020. Mr. Souza earned a salary of $385,417.00, a bonus of $24,000.00, options awards of $10,301,160.00, non-equity compensation of $1,001,000.00, and other compensation of $30,382.00. Learn More on Marcio Souza's salary.

How do I contact Marcio Souza?

The corporate mailing address for Mr. Souza and other Praxis Precision Medicines executives is 101 MAIN STREET #1210, CAMBRIDGE MA, 02142. Praxis Precision Medicines can also be reached via phone at 617-300-8460 and via email at [email protected] Learn More on Marcio Souza's contact information.

Has Marcio Souza been buying or selling shares of Praxis Precision Medicines?

During the last ninety days, Marcio Souza has bought $49,950.00 in shares of Praxis Precision Medicines stock. As an example of a recent trade by , 0 shares of the business's stock in a transaction on Wednesday, June 29th. Learn More on Marcio Souza's trading history.

Are insiders buying or selling shares of Praxis Precision Medicines?

In the last twelve months, Praxis Precision Medicines insiders bought shares 6 times. They purchased a total of 82,042 shares worth more than $281,483.18. In the last twelve months, insiders at the sold shares 6 times. They sold a total of 457,796 shares worth more than $8,513,858.62. The most recent insider tranaction occured on June, 16th when insider Lauren Mastrocola bought 3,000 shares worth more than $5,790.00. Insiders at Praxis Precision Medicines own 10.5 % of the company. Learn More about insider trades at Praxis Precision Medicines.

Information on this page was last updated on 6/16/2022.

Marcio Souza Insider Trading History at Praxis Precision Medicines

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/8/2022Buy27,000$1.85$49,950.00189,184View SEC Filing Icon  
8/18/2021Buy9,542$15.79$150,668.18View SEC Filing Icon  
11/10/2020Buy3,846$26.08$100,303.6824,450View SEC Filing Icon  
See Full Table

Marcio Souza Buying and Selling Activity at Praxis Precision Medicines

This chart shows Marcio Souza's buying and selling at Praxis Precision Medicines by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Praxis Precision Medicines Company Overview

Praxis Precision Medicines logo
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Read More

Today's Range

Now: $2.39
Low: $2.31
High: $2.61

50 Day Range

MA: $6.56
Low: $1.75
High: $10.95

2 Week Range

Now: $2.39
Low: $1.63
High: $23.56


1,843,163 shs

Average Volume

916,343 shs

Market Capitalization

$108.77 million

P/E Ratio


Dividend Yield



Soldiers Carry 20 Pounds of Lithium Batteries?
U.S. soldiers may carry up to 20 pounds of lithium batteries! In fact, nearly every American weapon defense system requires lithium batteries.
See Who Will Benefit From This Lithium Opportunity